AGIO Stock Overview
A biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. More details
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 2/6 |
Past Performance | 3/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Agios Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$54.41 |
52 Week High | US$62.58 |
52 Week Low | US$20.96 |
Beta | 0.75 |
11 Month Change | 19.16% |
3 Month Change | 19.06% |
1 Year Change | 147.77% |
33 Year Change | 46.07% |
5 Year Change | 39.30% |
Change since IPO | 73.95% |
Recent News & Updates
Recent updates
We're Not Very Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Rate
Sep 26Agios' Mitapivat: A Potential Blockbuster In Thalassemia Treatment
Aug 27Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Aug 04Agios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising Pipeline
Jun 12Companies Like Agios Pharmaceuticals (NASDAQ:AGIO) Are In A Position To Invest In Growth
Jun 02Bearish: Analysts Just Cut Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenue and EPS estimates
Feb 17Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation
Jan 16Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 50%
Nov 09Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation
Sep 26Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?
May 08We're Hopeful That Agios Pharmaceuticals (NASDAQ:AGIO) Will Use Its Cash Wisely
Feb 06Agios Pharmaceuticals (NASDAQ:AGIO) Is In A Good Position To Deliver On Growth Plans
Oct 18Agios Pyrukynd for rare blood disorder gets EMA panel backing for approval in EU
Sep 16Agios adds more than 13% after Novo deal to acquire rival Forma
Sep 01Agios Pharmaceuticals GAAP EPS of -$1.68 beats by $0.07
Aug 04Agios Pharmaceuticals Is A Buy On Coming Revenue Ramp
Jul 26Agios Pharmaceuticals appoints new board chair, CEO
Jul 12Agios: Approved Product, Upcoming Catalysts
May 10Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?
May 10Agios Pharmaceuticals With FDA Approval Is A Buy
Feb 23Agios Before The February PDUFA
Jan 20Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 46%
Dec 21Shareholder Returns
AGIO | US Biotechs | US Market | |
---|---|---|---|
7D | -7.2% | -7.5% | -1.2% |
1Y | 147.8% | 14.1% | 30.4% |
Return vs Industry: AGIO exceeded the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: AGIO exceeded the US Market which returned 30.4% over the past year.
Price Volatility
AGIO volatility | |
---|---|
AGIO Average Weekly Movement | 6.8% |
Biotechs Industry Average Movement | 9.7% |
Market Average Movement | 6.2% |
10% most volatile stocks in US Market | 15.5% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AGIO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: AGIO's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2007 | 385 | Brian Goff | www.agios.com |
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria.
Agios Pharmaceuticals, Inc. Fundamentals Summary
AGIO fundamental statistics | |
---|---|
Market cap | US$3.10b |
Earnings (TTM) | US$674.31m |
Revenue (TTM) | US$32.87m |
4.6x
P/E Ratio94.4x
P/S RatioIs AGIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
AGIO income statement (TTM) | |
---|---|
Revenue | US$32.87m |
Cost of Revenue | US$299.46m |
Gross Profit | -US$266.58m |
Other Expenses | -US$940.89m |
Earnings | US$674.31m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 11.82 |
Gross Margin | -811.00% |
Net Profit Margin | 2,051.38% |
Debt/Equity Ratio | 0% |
How did AGIO perform over the long term?
See historical performance and comparison